CoChat

DNA Methyltransferase Inhibitors Improve the Effect of Chemotherapeutic Agents in SW48 and HT-29 Colorectal Cancer Cells

Open access

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

DNA methylation is an epigenetic phenomenon known to play an important role in the development and progression of human cancer. Enzyme responsible for this process is DNA methyltransferase 1 (DNMT1) that maintains an altered methylation pattern by copying it from parent to daughter DNA strands after replication. Aberrant methylation of the promoter regions of genes critical for normal cellular functions is potentially reversible. Therefore, inactivation of DNMT1 seems to be a valuable target for the development of cancer therapies. Currently, the most popular DNMT inhibitors (DNMTi) are cytidine analogues like 5-azacytidine, 5-aza-2'-deoxycytidine (decitabine) and pyrimidin-2-one ribonucleoside (zebularine). In colorectal cancer, epigenetic modifications play an essential role at each step of carcinogenesis. Therefore, we have addressed the hypothesis that DNA methyltransferase inhibitors may potentiate inhibitory effects of classical chemotherapeutic agents, such as oxaliplatin and 5-fluorouracil (5-FU), commonly used in colorectal cancer therapy. Here, our report shows that DNMTi can have positive interactions with standard chemotherapeutics in colorectal cancer treatment. Using pharmacological models for the drug-drug interaction analysis, we have revealed that the combination of decitabine with 5-FU or oxaliplatin shows the most attractive interaction (synergism), whereas the effect of zebularine in combinations with chemotherapeutics is moderate and may be depended on genetic/epigenetic background of a cell line or secondary drug used in combination. Our results suggest that DNMTi administered in combination with standard chemotherapeutics might improve the treatment of patients with colorectal cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0092305

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effects of chemotherapeutic agents and DNMT inhibitors on cell viability of colorectal cancer cell lines. The cells were treated singly or in combinations with the indicted doses of the agents for 72; 5-FU, 5-fluorouracil; DAC, decitabine; and ZEB, zebularine. Each point represents the mean ±SD (n = 5), asterisks indicate a significance at P<0.05 for comparison with oxaliplatin or 5-FU alone.
Figure 1 Effects of chemotherapeutic agents and DNMT inhibitors on cell viability of colorectal cancer cell lines. The cells were treated singly or in combinations with the indicted doses of the agents for 72; 5-FU, 5-fluorouracil; DAC, decitabine; and ZEB, zebularine. Each point represents the mean ±SD (n = 5), asterisks indicate a significance at P<0.05 for comparison with oxaliplatin or 5-FU alone.CC BY · PubMed Central
Figure 2 Interactions of standard chemotherapeutics with DNMT inhibitors in the human colorectal cancer cell lines SW48 and HT-29. A. Isobolograms at a 50% effect level. Concentrations of particular drugs are indicated on x and y axis. The isobolograms were constructed by connecting the IC50 values of demethylating agents (on the ordinate) with the IC50 of oxaliplatin or 5-FU plotted on the abscissa. When the doses of two agents in combination are lower or higher than the additive doses, the synergy or antagonism is present, respectively. B. Combination index values (CI) with a 95% confidence interval at all effect levels as calculated by the CalcuSyn software. A CI value significantly less than 1 indicates synergy, a CI value insignificantly different from 1 indicates addition, and a CI significantly higher than 1 indicates antagonism.
Figure 2 Interactions of standard chemotherapeutics with DNMT inhibitors in the human colorectal cancer cell lines SW48 and HT-29. A. Isobolograms at a 50% effect level. Concentrations of particular drugs are indicated on x and y axis. The isobolograms were constructed by connecting the IC50 values of demethylating agents (on the ordinate) with the IC50 of oxaliplatin or 5-FU plotted on the abscissa. When the doses of two agents in combination are lower or higher than the additive doses, the synergy or antagonism is present, respectively. B. Combination index values (CI) with a 95% confidence interval at all effect levels as calculated by the CalcuSyn software. A CI value significantly less than 1 indicates synergy, a CI value insignificantly different from 1 indicates addition, and a CI significantly higher than 1 indicates antagonism.CC BY · PubMed Central
Figure 3 Combinations of chemotherapeutics with DNMTi agents induce major signaling checkpoints in response to DNA damage. A. Quantification of ATR and ATM phosphorylation level following 72(MFI) was used. Data represented the mean ±SD (n = 3). Significant difference at P≤0.05 is indicated by an asterisk (*). B. Analysis of protein phosphorylation levels using Western blotting method. The detection of β-actin was used as a gel loading control. OXA, oxaliplatin; 5-FU, 5-fluorouracil; DAC, decitabine; ZEB, zebularine; a.u., arbitrary units.
Figure 3 Combinations of chemotherapeutics with DNMTi agents induce major signaling checkpoints in response to DNA damage. A. Quantification of ATR and ATM phosphorylation level following 72(MFI) was used. Data represented the mean ±SD (n = 3). Significant difference at P≤0.05 is indicated by an asterisk (*). B. Analysis of protein phosphorylation levels using Western blotting method. The detection of β-actin was used as a gel loading control. OXA, oxaliplatin; 5-FU, 5-fluorouracil; DAC, decitabine; ZEB, zebularine; a.u., arbitrary units.CC BY · PubMed Central
Figure 4 Chemotherapeutic agents, DNMTi and their combinations influence the cell cycle progression of colorectal cancer cells. A. Changes in the cell cycle distribution of SW48 and HT-29 cells after 72 h of treatment with the evaluated agents. The cells were stained with propidium iodide (PI) and then analyzed by flow cytometry. The percentage of cells in each phase of the cell cycle was determined using ModFit LT™ (version 3.0). Each bar represents the mean ±S.D. (n≥4). Significant difference at P<0.05 are indicated by asterisk (*). B. Analysis of CCNE1 and ATM mRNA levels by semi-quantitative RT-PCR method after 72 h incubation of CRC cells with chemotherapeutic agents, DNMTi and their combinations at concentrations as indicated. M, marker [bp]; GAPDH, transcript encoding glyceraldehyde-3-phosphate dehydrogenase, a constitutively expressed gene, used as an internal control. C. Western blotting analysis of the cell cycle regulatory proteins. The β-actin was used as a gel loading control. OXA, oxaliplatin; 5-FU, 5-fluorouracil; DAC, decitabine; ZEB, zebularine.
Figure 4 Chemotherapeutic agents, DNMTi and their combinations influence the cell cycle progression of colorectal cancer cells. A. Changes in the cell cycle distribution of SW48 and HT-29 cells after 72 h of treatment with the evaluated agents. The cells were stained with propidium iodide (PI) and then analyzed by flow cytometry. The percentage of cells in each phase of the cell cycle was determined using ModFit LT™ (version 3.0). Each bar represents the mean ±S.D. (n≥4). Significant difference at P<0.05 are indicated by asterisk (*). B. Analysis of CCNE1 and ATM mRNA levels by semi-quantitative RT-PCR method after 72 h incubation of CRC cells with chemotherapeutic agents, DNMTi and their combinations at concentrations as indicated. M, marker [bp]; GAPDH, transcript encoding glyceraldehyde-3-phosphate dehydrogenase, a constitutively expressed gene, used as an internal control. C. Western blotting analysis of the cell cycle regulatory proteins. The β-actin was used as a gel loading control. OXA, oxaliplatin; 5-FU, 5-fluorouracil; DAC, decitabine; ZEB, zebularine.CC BY · PubMed Central
Figure 5 Induction of apoptosis in colorectal cancer cells following 72 h incubation with chemotherapeutic agents, DNMT inhibitors and their combinations. A. Detection of apoptosis by the annexin V-fluorescein isothiocyanate (FITC)/porpidium iodide (PI) analysis. Data are expressed as the means ±S.D. (n≥4). An asterisk (*) indicates that the induction of apoptosis by the evaluated agents was significant in comparison with the combination of chemotherapeutic agents and DNMT inhibitors versus chemotherapeutic agents applied alone (P<0.05). B. Western blotting analysis of pro-apoptotic protein levels. The β-actin was used as a gel loading control. C. Representative cytograms of flow cytometry experiments demonstrating changes in ΔΨm in CRC cells lines after 72 h of incubation with chemotherapeutic agents, DNMT inhibitors and their combinations. Cells were stained with JC-1. Cells in the R2 quadrant were counted as cells deprived of mitochondrial membrane potential. An asterisk (*) indicates a significant difference between experimental groups and control group at P<0.05. OXA, oxaliplatin; 5-FU, 5-fluorouracil; DAC, decitabine; ZEB, zebularine.
Figure 5 Induction of apoptosis in colorectal cancer cells following 72 h incubation with chemotherapeutic agents, DNMT inhibitors and their combinations. A. Detection of apoptosis by the annexin V-fluorescein isothiocyanate (FITC)/porpidium iodide (PI) analysis. Data are expressed as the means ±S.D. (n≥4). An asterisk (*) indicates that the induction of apoptosis by the evaluated agents was significant in comparison with the combination of chemotherapeutic agents and DNMT inhibitors versus chemotherapeutic agents applied alone (P<0.05). B. Western blotting analysis of pro-apoptotic protein levels. The β-actin was used as a gel loading control. C. Representative cytograms of flow cytometry experiments demonstrating changes in ΔΨm in CRC cells lines after 72 h of incubation with chemotherapeutic agents, DNMT inhibitors and their combinations. Cells were stained with JC-1. Cells in the R2 quadrant were counted as cells deprived of mitochondrial membrane potential. An asterisk (*) indicates a significant difference between experimental groups and control group at P<0.05. OXA, oxaliplatin; 5-FU, 5-fluorouracil; DAC, decitabine; ZEB, zebularine.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 53

Metadata

Authors
Flis, S., Gnyszka, A., & Flis, K.
Affiliations
  • Narodowy Instytut Leków (PL)
  • Institute of Biochemistry and Biophysics, Polish Academy of Sciences (PL)
Corresponding author
Flis, Sylwia
Venue
PLoS ONE
Published
2014-03-27
Volume
9
Issue
3
Pages
e92305
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1966590731
Cited by
53
References
40
Citations by year
2025: 5 · 2024: 4 · 2023: 1 · 2022: 6 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 5 · 2017: 9 · 2016: 4 · 2015: 6 · 2014: 3
FWCI
3.01
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
Keywords
hypomethylating agents, colorectal cancer, epigenetic therapy, decitabine, zebularine, azacitidine, oxaliplatin, 5-fluorouracil, drug-drug interactions, synergistic effect, SW48 cells, HT-29 cells, DNA methylation
MeSH terms
Oxaliplatin, Decitabine, Antineoplastic Combined Chemotherapy Protocols, Azacitidine, Cell Cycle, Cytidine, DNA Damage, Enzyme Inhibitors, Fluorouracil, Humans, Organoplatinum Compounds, Colorectal Neoplasms, DNA-Cytosine Methylases, Apoptosis, Cell Line, Tumor, Membrane Potential, Mitochondrial

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: DNA Methyltransferase Inhibitors Improve the Effect of Chemotherapeutic Agents in SW48 and HT-29 Colorectal Cancer Cells. https://app.cochat.ai/papers/10.1371/journal.pone.0092305
The paper
Flis, S., Gnyszka, A., & Flis, K. (2014). DNA Methyltransferase Inhibitors Improve the Effect of Chemotherapeutic Agents in SW48 and HT-29 Colorectal Cancer Cells. PLoS ONE. https://doi.org/10.1371/journal.pone.0092305

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.